Biogen validated the Alzheimer's tau theory. CEO Viehbacher still isn't betting the store
biospace.com
Biogen's Phase 2 CELIA trial showed lowering tau may improve Alzheimer's outcomes — yet the CEO won't go all-in, raising the question of how much one trial should move the needle.
Scientific Paradigm ShiftBayesian UpdatingRisk ManagementPrincipal-Agent Problem
Theory Briefing
- Biogen's Phase 2 CELIA trial produced early data suggesting that reducing tau protein can improve Alzheimer's outcomes, a long-contested scientific bet.
- Despite the apparent validation, CEO Viehbacher is deliberately avoiding an all-or-nothing commitment to the tau hypothesis.
- The tau theory competes with the dominant amyloid hypothesis, and one Phase 2 readout is rarely enough to settle a decades-long scientific debate.
- Biogen's cautious posture reflects how costly prior Alzheimer's theory bets — including its own amyloid stumbles — have been for the industry.